Christian Rolfo, MD, PhD, MBA, The Tisch Cancer Institute at Mount Sinai, New York, NY, discusses the role of liquid biopsies in monitoring progression in lung cancer. Patients responses to targeted therapies and immunotherapies can be monitored with liquid biopsies as well as identify patients who have complete responses and hence can stop therapy. Prof. Rolfo additionally highlights TGF-β as a promising biomarker of progression on checkpoint inhibitors, as well as strategies to integrate liquid biopsies in clinical trials. This interview took place at the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.